Cargando…
Hepatitis E virus infection in the United States: Seroprevalence, risk factors and the influence of immunological assays
In the United States (U.S.), a hepatitis E virus (HEV) seroprevalence between 6 and 21% has been described, with a decreasing trend. We aimed to investigate HEV infection in the U.S. population from 2009 to 2016, and examine the differences in seroprevalence using different assays. We used data from...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9355204/ https://www.ncbi.nlm.nih.gov/pubmed/35930611 http://dx.doi.org/10.1371/journal.pone.0272809 |
_version_ | 1784763241694494720 |
---|---|
author | Pisano, María Belén Campbell, Christopher Anugwom, Chimaobi Ré, Viviana Elizabeth Debes, José D. |
author_facet | Pisano, María Belén Campbell, Christopher Anugwom, Chimaobi Ré, Viviana Elizabeth Debes, José D. |
author_sort | Pisano, María Belén |
collection | PubMed |
description | In the United States (U.S.), a hepatitis E virus (HEV) seroprevalence between 6 and 21% has been described, with a decreasing trend. We aimed to investigate HEV infection in the U.S. population from 2009 to 2016, and examine the differences in seroprevalence using different assays. We used data from the National Health and Nutrition Examination Survey (NHANES-CDC) to estimate HEV seroprevalence and analyze demographic variables related to the infection. Additionally, we compared 4 serological tests used. The estimated HEV seroprevalence between 2009–2016 was 6.1% (95% CI: 5.6%-7.0%) for IgG and 1.02% (0.8%-1.2%) for IgM. Higher HEV IgG prevalences were found in older people, females, non-Hispanic Asians and those born outside of the U.S. The in-house immunoassay and the Wantai HEV-IgG ELISA presented the highest sensitivity values in the tested population. The highest specificity values corresponded to the DSI-EIA-ANTI-HEV-IgG assay. The kappa statistical values showed concordances no greater than 0.64 between the assays. HEV prevalence in our study was similar to previously reported, and a decline in the prevalence was observed through the NHANES assessments (from 1988 to 2016). The sensitivity and specificity of the assays varied widely, making comparisons difficult and highlighting the need to develop a gold standard assay. |
format | Online Article Text |
id | pubmed-9355204 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-93552042022-08-06 Hepatitis E virus infection in the United States: Seroprevalence, risk factors and the influence of immunological assays Pisano, María Belén Campbell, Christopher Anugwom, Chimaobi Ré, Viviana Elizabeth Debes, José D. PLoS One Research Article In the United States (U.S.), a hepatitis E virus (HEV) seroprevalence between 6 and 21% has been described, with a decreasing trend. We aimed to investigate HEV infection in the U.S. population from 2009 to 2016, and examine the differences in seroprevalence using different assays. We used data from the National Health and Nutrition Examination Survey (NHANES-CDC) to estimate HEV seroprevalence and analyze demographic variables related to the infection. Additionally, we compared 4 serological tests used. The estimated HEV seroprevalence between 2009–2016 was 6.1% (95% CI: 5.6%-7.0%) for IgG and 1.02% (0.8%-1.2%) for IgM. Higher HEV IgG prevalences were found in older people, females, non-Hispanic Asians and those born outside of the U.S. The in-house immunoassay and the Wantai HEV-IgG ELISA presented the highest sensitivity values in the tested population. The highest specificity values corresponded to the DSI-EIA-ANTI-HEV-IgG assay. The kappa statistical values showed concordances no greater than 0.64 between the assays. HEV prevalence in our study was similar to previously reported, and a decline in the prevalence was observed through the NHANES assessments (from 1988 to 2016). The sensitivity and specificity of the assays varied widely, making comparisons difficult and highlighting the need to develop a gold standard assay. Public Library of Science 2022-08-05 /pmc/articles/PMC9355204/ /pubmed/35930611 http://dx.doi.org/10.1371/journal.pone.0272809 Text en © 2022 Pisano et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Pisano, María Belén Campbell, Christopher Anugwom, Chimaobi Ré, Viviana Elizabeth Debes, José D. Hepatitis E virus infection in the United States: Seroprevalence, risk factors and the influence of immunological assays |
title | Hepatitis E virus infection in the United States: Seroprevalence, risk factors and the influence of immunological assays |
title_full | Hepatitis E virus infection in the United States: Seroprevalence, risk factors and the influence of immunological assays |
title_fullStr | Hepatitis E virus infection in the United States: Seroprevalence, risk factors and the influence of immunological assays |
title_full_unstemmed | Hepatitis E virus infection in the United States: Seroprevalence, risk factors and the influence of immunological assays |
title_short | Hepatitis E virus infection in the United States: Seroprevalence, risk factors and the influence of immunological assays |
title_sort | hepatitis e virus infection in the united states: seroprevalence, risk factors and the influence of immunological assays |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9355204/ https://www.ncbi.nlm.nih.gov/pubmed/35930611 http://dx.doi.org/10.1371/journal.pone.0272809 |
work_keys_str_mv | AT pisanomariabelen hepatitisevirusinfectionintheunitedstatesseroprevalenceriskfactorsandtheinfluenceofimmunologicalassays AT campbellchristopher hepatitisevirusinfectionintheunitedstatesseroprevalenceriskfactorsandtheinfluenceofimmunologicalassays AT anugwomchimaobi hepatitisevirusinfectionintheunitedstatesseroprevalenceriskfactorsandtheinfluenceofimmunologicalassays AT revivianaelizabeth hepatitisevirusinfectionintheunitedstatesseroprevalenceriskfactorsandtheinfluenceofimmunologicalassays AT debesjosed hepatitisevirusinfectionintheunitedstatesseroprevalenceriskfactorsandtheinfluenceofimmunologicalassays |